top of page


 Bringing a SEA change to biologics
Safety, Efficacy and Access

Fzata is honored to be:

  • A Maryland Company @ BIO 2024 representing MD Dept. of Commerce 

  • NIH Innovation Zone Company @BIO 2023 

  • Recipient of $17MM in NIH grants

Bioengineered Probiotic Yeast Medicine (BioPYM): a first-in-class platform for oral live biotherapeutics.   5 July 2023

Capsule labeled "BioPYM" and outline of head preparing to swallow capsule.

Intro Video 2 min.

Our Vision

Vision :  Expand safety, efficacy & access for therapeutic biologics leveraging BioPYM  oral administration  


Our oral biologics for gastrointestinal (GI) disorders will:

  1. Improve patient safety with no systemic toxicities

  2. Improve efficacy with biologics targeted directly to GI where disease occurs

  3.  Improve patient accessibility to biologics with at home, non-refrigerated, convenient oral capsules

  4.  Improve patient compliance with no needles and no  health-care administrated infusion

  5.  Improve chronic use outcomes given the high safety profile, no ADA, no systemic toxicity

The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) uses yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.  

syringe under prohibition sign

 Fzata, Inc. 1450 S. Rolling Rd,  Room 4.097,  Halethorpe, Maryland 21227  USA


Award-winning Company


Fzata is an NIH Innovation Zone Winner 
for BIO Intl. 2023 in Boston

Innovation Celebration Winner Biotechnology
bottom of page